Bavarian Nordic (CPSE:BAVA) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BAVA Overzicht aandelen

Bavarian Nordic A/S ontwikkelt, produceert en verkoopt levensreddende vaccins.

BAVA fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	1/6
Prestaties in het verleden	1/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 80.2% onder onze schatting van de reële waarde

De winst zal naar verwachting met 9.69% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Winstmarges (11.6%) zijn lager dan vorig jaar (19.5%)

Volatiele aandelenkoers in de afgelopen 3 maanden

Grote eenmalige posten die de financiële resultaten beïnvloeden

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Bavarian Nordic A/S Concurrenten

Genmab

CPSE:GMAB

DKK 99.3b

PeptiDream

TSE:4587

JP¥382.4b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

ALK-Abelló

CPSE:ALK B

DKK 38.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bavarian Nordic
Historische aandelenkoersen
Huidige aandelenkoers	DKK 217.10
52 Week Hoogtepunt	DKK 300.00
52 Week Laag	DKK 125.55
Bèta	1.54
11 maand verandering	-10.66%
3 maanden verandering	17.35%
1 Jaar Verandering	65.92%
33 jaar verandering	-30.08%
5 jaar verandering	34.26%
Verandering sinds IPO	-14.86%

Recent nieuws en updates

Recent updates

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Aug 26

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Aug 25

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Aug 09

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Jul 11

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

May 12

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Feb 26

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Jan 03

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Dec 10

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Nov 15

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Aug 17

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 19

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Jan 03

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Sep 15

Rendement voor aandeelhouders

	BAVA	DK Biotechs	DK Markt
7D	2.9%	0.3%	-0.9%
1Y	65.9%	6.8%	19.7%

Rendement versus industrie: BAVA overtrof de Danish Biotechs industrie, die het afgelopen jaar een rendement -5.1 % opleverde.

Rendement versus markt: BAVA overtrof de Danish markt, die het afgelopen jaar een rendement opleverde van 21.8 %.

Prijsvolatiliteit

Is BAVA's price volatile compared to industry and market?
BAVA volatility
BAVA Average Weekly Movement	8.9%
Biotechs Industry Average Movement	7.9%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	8.9%
10% least volatile stocks in DK Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van BAVA is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van BAVA is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Danish.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1992	1,381	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S ontwikkelt, produceert en verkoopt levensreddende vaccins. Het bedrijf biedt niet-replicerende pokken- en apenpokkenvaccins onder de namen IMVAMUNE, IMVANEX en JYNNEOS; rabiësvaccin voor menselijk gebruik onder de naam Rabipur/RabAvert; tekenencefalitisvaccin onder de naam Encepur; en ebolavaccin onder de naam MVABEA. Het ontwikkelt ook MVA-BN voor de behandeling van pokken; MVA-BN RSV, dat zich in Fase III van de klinische testen bevindt voor de behandeling van respiratoir syncytieel virus; ABNCoV2 dat Fase III van de klinische testen voor de behandeling van SARS-CoV-2 heeft afgerond.

Bavarian Nordic A/S Samenvatting

Hoe verhouden de winst en inkomsten van Bavarian Nordic zich tot de beurswaarde?
BAVA fundamentele statistieken
Marktkapitalisatie	DKK 17.05b
Inkomsten(TTM)	DKK 707.42m
Inkomsten(TTM)	DKK 6.08b

24.1x

Koers/Winstverhouding

2.8x

P/S-verhouding

Is BAVA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BAVA resultatenrekening (TTM)
Inkomsten	DKK 6.08b
Kosten van inkomsten	DKK 2.06b
Brutowinst	DKK 4.02b
Overige uitgaven	DKK 3.31b
Inkomsten	DKK 707.42m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 15, 2024

Winst per aandeel (EPS)	9.01
Brutomarge	66.08%
Nettowinstmarge	11.63%
Schuld/Eigen Vermogen Verhouding	0.2%

Hoe presteerde BAVA op de lange termijn?

Bekijk historische prestaties en vergelijking

BAVA Overzicht aandelen

Beloningen

Risicoanalyse

Bavarian Nordic A/S Concurrenten

CPSE:GMAB

DKK 99.3b

TSE:4587

JP¥382.4b

NasdaqCM:CPRX

US$2.5b

CPSE:ALK B

DKK 38.2b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Price target increased by 9.0% to kr.312

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

CEO & President exercised options to buy kr.24m worth of stock.

Recent updates

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Price target increased by 9.0% to kr.312

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

CEO & President exercised options to buy kr.24m worth of stock.

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Consensus EPS estimates increase by 56%

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Price target increased by 8.7% to kr.286

Second quarter 2024 earnings: Revenues exceed analyst expectations

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

New major risk - Share price stability

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Investor sentiment improves as stock rises 18%

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Investor sentiment improves as stock rises 18%

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Deputy Chairman exercised options to buy kr.123k worth of stock.

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

CEO & President exercised options to buy kr.1.4m worth of stock.

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Price target increased by 9.4% to kr.293

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Consensus EPS estimates increase by 40%

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.